BioCentury | Jun 30, 2017
Clinical News

Xenetic begins Phase II of XBIO-101 in endometrial cancer

...increases PGR expression. Xenetic has worldwide rights to develop and commercialize XBIO-101 from Pharmsynthez JSC (MICEX:LIFE). Pharmsynthez...
...the Commonwealth of Independent States (CIS), excluding oncology indications (see BioCentury, Dec. 21, 2015 ). Pharmsynthez JSC...
...disease and overall survival (OS) Status: Phase II started Milestone: NA Julian Zhu Xenetic Biosciences Inc. Progesterone receptor (PGR) Pharmsynthez JSC sodium...
BioCentury | Dec 21, 2015
Company News

Pharmsynthez, Kevelt, Xenetic deal

...Xenetic will purchase worldwide rights to develop and commercialize Virexxa from Kevelt and Pharmsynthez for 111.5...
...to provide additional details, while Xenetic and Pharmasynthez did not respond in time for publication. Pharmsynthez JSC...
BioCentury | Jul 13, 2015
Financial News

Xenetic completes private placement of senior convertible notes

...Private placement of senior convertible notes Raised: $3 million Shares outstanding prior: 150 million Investor: Pharmsynthez...
...senior secured note bears 10% interest, matures on July 1, 2016, and converts at $0.15. Pharmsynthez...
BioCentury | Dec 15, 2014
Clinical News

MyeloXen: Phase I/IIa ongoing

...Xenetic said Pharmsynthez completed dosing in a 3-part, open-label, Russian Phase I/IIa trial evaluating MyeloXen in...
...MS. The second dose-escalation part determined the dose levels for use in the third part. Pharmsynthez...
...Xenetic has rights elsewhere (see BioCentury, Nov. 23, 2009). Xenetic Biosciences Inc. (OTCBB:XBIO), Lexington, Mass. Pharmsynthez JSC...
BioCentury | May 26, 2014
Clinical News

PSA-Oxyntomodulin: Phase I data

...0.25, 0.75 and 1.5 mg/kg subcutaneous PSA-Oxyntomodulin were well tolerated. The trial was conducted by Pharmsynthez...
...The partners could not be reached for next steps. Xenetic Biosciences Inc. (OTCBB:XBIO), Lexington, Mass. Pharmsynthez JSC...
BioCentury | Apr 14, 2014
Clinical News

PulmoXen: Phase I data

...once-daily 2,500 and 5,000 IU doses of inhaled PulmoXen for 7 days were well tolerated. Pharmsynthez...
...to disclose details. Xenetic has rights to develop and commercialize PulmoXen outside of Russia from Pharmsynthez...
...under a 2009 deal (see BioCentury, Nov. 23, 2009). Xenetic Biosciences Inc. (OTCBB:XBIO), London, U.K. Pharmsynthez JSC...
BioCentury | Feb 3, 2014
Company News

Pharmsynthez, Rafarma Pharmaceuticals deal

...Pharmsynthez's products. Rafarma said the plan would double manufacturing capacity. The deal will close after Pharmsynthez's...
...which of Pharmsynthez's products would be included under the deal. Pharmsynthez is an API manufacturer. Pharmsynthez JSC...
BioCentury | Dec 9, 2013
Clinical News

PulmoXen: Phase I started

...Xenetic said Pharmsynthez began an open-label, Russian Phase I trial to evaluate 2,500 and 5,000 units...
...2009 deal with Pharmsynthez (see BioCentury, Nov. 23, 2009). Xenetic Biosciences plc (LSE:XEN), London, U.K. Pharmsynthez JSC...
BioCentury | Dec 9, 2013
Clinical News

PSA-Oxyntomodulin: Phase I started

...Xenetic said Pharmsynthez began a placebo-controlled, Russian Phase I trial to evaluate 3 dose levels of...
...2009 deal with Pharmsynthez (see BioCentury, Nov. 23, 2009). Xenetic Biosciences plc (LSE:XEN), London, U.K. Pharmsynthez JSC...
BioCentury | May 6, 2013
Company News

Opko, Pharmsynthez deal

...Opko acquired about a 10% stake in Russian pharmaceutical company Pharmsynthez. Opko said it made the...
...investment and the following partnership will expand commercial reach in Russian and Eastern European markets. Pharmsynthez's...
...Opko and Pharmsynthez could not be reached for details. Opko Health Inc. (NYSE:OPK), Miami, Fla. Pharmsynthez JSC...
Items per page:
1 - 10 of 23
BioCentury | Jun 30, 2017
Clinical News

Xenetic begins Phase II of XBIO-101 in endometrial cancer

...increases PGR expression. Xenetic has worldwide rights to develop and commercialize XBIO-101 from Pharmsynthez JSC (MICEX:LIFE). Pharmsynthez...
...the Commonwealth of Independent States (CIS), excluding oncology indications (see BioCentury, Dec. 21, 2015 ). Pharmsynthez JSC...
...disease and overall survival (OS) Status: Phase II started Milestone: NA Julian Zhu Xenetic Biosciences Inc. Progesterone receptor (PGR) Pharmsynthez JSC sodium...
BioCentury | Dec 21, 2015
Company News

Pharmsynthez, Kevelt, Xenetic deal

...Xenetic will purchase worldwide rights to develop and commercialize Virexxa from Kevelt and Pharmsynthez for 111.5...
...to provide additional details, while Xenetic and Pharmasynthez did not respond in time for publication. Pharmsynthez JSC...
BioCentury | Jul 13, 2015
Financial News

Xenetic completes private placement of senior convertible notes

...Private placement of senior convertible notes Raised: $3 million Shares outstanding prior: 150 million Investor: Pharmsynthez...
...senior secured note bears 10% interest, matures on July 1, 2016, and converts at $0.15. Pharmsynthez...
BioCentury | Dec 15, 2014
Clinical News

MyeloXen: Phase I/IIa ongoing

...Xenetic said Pharmsynthez completed dosing in a 3-part, open-label, Russian Phase I/IIa trial evaluating MyeloXen in...
...MS. The second dose-escalation part determined the dose levels for use in the third part. Pharmsynthez...
...Xenetic has rights elsewhere (see BioCentury, Nov. 23, 2009). Xenetic Biosciences Inc. (OTCBB:XBIO), Lexington, Mass. Pharmsynthez JSC...
BioCentury | May 26, 2014
Clinical News

PSA-Oxyntomodulin: Phase I data

...0.25, 0.75 and 1.5 mg/kg subcutaneous PSA-Oxyntomodulin were well tolerated. The trial was conducted by Pharmsynthez...
...The partners could not be reached for next steps. Xenetic Biosciences Inc. (OTCBB:XBIO), Lexington, Mass. Pharmsynthez JSC...
BioCentury | Apr 14, 2014
Clinical News

PulmoXen: Phase I data

...once-daily 2,500 and 5,000 IU doses of inhaled PulmoXen for 7 days were well tolerated. Pharmsynthez...
...to disclose details. Xenetic has rights to develop and commercialize PulmoXen outside of Russia from Pharmsynthez...
...under a 2009 deal (see BioCentury, Nov. 23, 2009). Xenetic Biosciences Inc. (OTCBB:XBIO), London, U.K. Pharmsynthez JSC...
BioCentury | Feb 3, 2014
Company News

Pharmsynthez, Rafarma Pharmaceuticals deal

...Pharmsynthez's products. Rafarma said the plan would double manufacturing capacity. The deal will close after Pharmsynthez's...
...which of Pharmsynthez's products would be included under the deal. Pharmsynthez is an API manufacturer. Pharmsynthez JSC...
BioCentury | Dec 9, 2013
Clinical News

PulmoXen: Phase I started

...Xenetic said Pharmsynthez began an open-label, Russian Phase I trial to evaluate 2,500 and 5,000 units...
...2009 deal with Pharmsynthez (see BioCentury, Nov. 23, 2009). Xenetic Biosciences plc (LSE:XEN), London, U.K. Pharmsynthez JSC...
BioCentury | Dec 9, 2013
Clinical News

PSA-Oxyntomodulin: Phase I started

...Xenetic said Pharmsynthez began a placebo-controlled, Russian Phase I trial to evaluate 3 dose levels of...
...2009 deal with Pharmsynthez (see BioCentury, Nov. 23, 2009). Xenetic Biosciences plc (LSE:XEN), London, U.K. Pharmsynthez JSC...
BioCentury | May 6, 2013
Company News

Opko, Pharmsynthez deal

...Opko acquired about a 10% stake in Russian pharmaceutical company Pharmsynthez. Opko said it made the...
...investment and the following partnership will expand commercial reach in Russian and Eastern European markets. Pharmsynthez's...
...Opko and Pharmsynthez could not be reached for details. Opko Health Inc. (NYSE:OPK), Miami, Fla. Pharmsynthez JSC...
Items per page:
1 - 10 of 23